The National Human Rights Commission (NHRC) has taken suo motu cognisance of a media report that after the alert from the World Health Organization (WHO), the Central Drugs Standard Control Organisation (CDSCO) has asked the State regulators, doctors and patients to remain vigilant about two medicines, namely liver drug Defitalio and cancer drug Adcetris, as the falsified versions of these drugs are circulating in four countries, including India.
Reportedly, the falsified versions of Adcetris injection 50 mg, detected in four countries, including India are most often found to be available at the patient level and distributed in unregulated supply chains (mainly online).
According to the reports, the product does not have marketing authorisation in India and Turkey. However, the falsified versions of the liver medicine Defitalio were detected in India and Turkey, which were supplied outside of regulated and authorised channels.
